Overview

This trial is active, not recruiting.

Condition teeth loss
Treatments standard plus esta stl roxolid implant, standard plus stl implant
Sponsor Institut Straumann AG
Start date January 2012
End date September 2013
Trial size 43 participants
Trial identifier NCT02159183, CR 01/11

Summary

This study will investigate the effect on the soft tissue that is in contact with a dental implant with a modified surface of the neck (the part of the implant that is above the bone and in contact with the soft gum tissue).

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Allocation randomized
Endpoint classification safety/efficacy study
Intervention model parallel assignment
Masking single blind (subject)
Primary purpose treatment
Arm
(Experimental)
This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA).
standard plus esta stl roxolid implant
The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø 4.1 mm Regular Neck, SLActive® Roxolid, with a modified surface of the neck (ESTA). At 8-12 weeks after insertion, the implant will be loaded.
(Active Comparator)
This arm will receive the Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck.
standard plus stl implant
The patient will receive a Straumann Soft Tissue Level Standard Plus Implant Ø4.1mm Regular Neck,SLActive® Titanium grade IV, with a machined surface of the neck. At 8-12 weeks after insertion, the implant will be loaded.

Primary Outcomes

Measure
Sulcus Bleeding Index (according to Mombelli et al 1987)
time frame: 12 months

Secondary Outcomes

Measure
Sulcus Bleeding Index (according to Mombelli et al 1987)
time frame: 3 and 5 years
Soft tissue healing evaluation
time frame: 10 days and 12 weeks
Plaque accumulation
time frame: at each visit (up to 5 years)
Evaluation of mucosal inflammatory markers
time frame: up to 1 year
Microbiological evaluation of plaque collected
time frame: up to 1 year
Recession of gingival margin buccally and lingually/palatal
time frame: 1, 3 and 5 years
Probing pocket depth (PPD)
time frame: 6 months, 1, 3 and 5 years
Clinical attachment level (CAL)
time frame: 6 months, 1, 3 and 5 years
Bone crest levels
time frame: 1,3 and 5 years
Dental implant success and survival rates
time frame: 1, 3 and 5 years
Adverse events
time frame: up to 5 years

Eligibility Criteria

Male or female participants from 18 years up to 80 years old.

Inclusion Criteria: - Subjects must have voluntarily signed the informed consent form before any study related action - Males and females must be at least 18 years of age and not more than 80 years old. - Partially edentulous in posterior (position 3-7) maxilla or mandible with implants planned for single crowns in an area with a healed extraction socket. - Adequate bone quality and quantity at the implant site to permit the insertion of a Straumann Soft Tissue Level implant of 4.1mm diameter without augmentation (at least 1mm bone buccally and lingually/palatal) Exclusion Criteria: - Oral surgery contraindicated according to the judgement of the investigator (should be explained in the CRF) - Local inflammation, including untreated periodontitis - Patients with inadequate oral hygiene or unmotivated for adequate home care. Full mouth plaque index > 25% at time of surgery - Presence of conditions requiring chronic routine prophylactic use of antibiotics (e.g., history of rheumatic heart disease, bacterial endocarditis, cardiac valvular anomalies, prosthetic joint replacements) - Major systemic diseases - Medical conditions requiring prolonged use of steroids - Current pregnancy or breastfeeding women - Physical handicaps that would interfere with the ability to perform adequate oral hygiene - Use of any investigational drug or device within the 90 day period immediately prior to implant surgery on study day 0 - Alcoholism or chronically drug abuse - Smokers; more than 10 cigarettes per day - Immuno-compromised patients - Conditions or circumstances, in the opinion of the investigator, which would prevent completion of study participation or interfere with analysis of study results, such as history of non-compliance, or unreliability. Secondary Exclusion Criteria: - GBR procedures at or adjacent to the planned study site - Lack of primary stability of the dental implant at site of interest (e.g., rotational movement of the implant at a minimum of 15 Ncm torque at connection of the healing abutment, or tactile mobility)

Additional Information

Official title A Controlled Clinical Pilot Study to Assess Soft Tissue Reaction at the Crestal Part of a Dental Implant With ESTA Surface
Principal investigator Anton Sculean, Prof. Dr.
Description This is a prospective, controlled, randomised clinical pilot study with parallel groups and blinded subject. The design has been chosen to obtain data to base a sample size calculation for future studies on by comparing the degree of mucosal inflammation of the mucosa in conjunction with the modified surface of the top of the test implant and the machined surface on the top of the control implant.
Trial information was received from ClinicalTrials.gov and was last updated in March 2016.
Information provided to ClinicalTrials.gov by Institut Straumann AG.